Wave Life Sciences Ltd. (FRA:1U5)

Market Cap	1.09B
Revenue (ttm)	93.10M
Net Income (ttm)	-103.93M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	137
Open	6.25
Previous Close	5.85
Day's Range	6.25 - 6.25
52-Week Range	4.62 - 14.60
Beta	n/a
RSI	46.49
Earnings Date	Mar 4, 2026

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 288
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1U5

Financial Performance

In 2024, Wave Life Sciences's revenue was $108.30 million, a decrease of -4.42% compared to the previous year's $113.31 million. Losses were -$97.01 million, 68.7% more than in 2023.

Financial numbers in USD